Literature DB >> 20379728

Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord.

Heiko Braak1, Albert Ludolph, Dietmar R Thal, Kelly Del Tredici.   

Abstract

Skein-like and spherical inclusions within the somatodendritic compartment of a few types of susceptible neurons in the human nervous system are the currently acknowledged pathological hallmarks of amyotrophic lateral sclerosis (ALS). These inclusions consist chiefly of an aggregated, phosphorylated, and ultimately ubiquitinated intranuclear protein, TDP-43. To investigate the development of these inclusions, a single neuronal type that is susceptible to the ALS-associated pathological process, i.e., the class of large multipolar somatomotor neurons in the lower brainstem and spinal cord, was studied in four cases of sporadic ALS and four age-matched controls using immunoreactions against phosphorylated TDP-43 (pTDP-43), p62, and ubiquitin. In these neurons, the protein TDP-43, after its displacement outside of the cell nucleus and abnormal phosphorylation, forms light microscopically visible dash-like aggregates which were dispersed throughout their entire somatodendritic domain and even extended into the proximal portions of the axon. Many motor neurons contained these lesions, which were not detectable with anti-TDP-43 and anti-p62. In an additional step, a small number of the neurons that contain the dash-like lesions displayed a clustering of the aggregated material, which forms thick net-like (potential precursors of the skein-like inclusions) and spherical inclusions. This material, in turn, was ubiquitinated and p62-immunopositive. Thus, dash-like pTDP-43 aggregates are regularly seen in motor neurons in ALS and may represent the initial cellular lesion in this disease. Because these aggregates were not stained with antibodies against p62 and non-phosphorylated TDP-43, it is possible that phosphorylation of TDP-43 is required for its aggregation in sporadic ALS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20379728     DOI: 10.1007/s00401-010-0683-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  22 in total

Review 1.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

2.  Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy.

Authors:  Felix Geser; Beth Stein; Michael Partain; Lauren B Elman; Leo F McCluskey; Sharon X Xie; Vivianna M Van Deerlin; Linda K Kwong; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-01-12       Impact factor: 17.088

3.  Motor neuron disease: urgently needed-biomarkers for amyotrophic lateral sclerosis.

Authors:  Albert C Ludolph
Journal:  Nat Rev Neurol       Date:  2011-01       Impact factor: 42.937

Review 4.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

Review 5.  Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Authors:  Rachna S Pandya; Haining Zhu; Wei Li; Robert Bowser; Robert M Friedlander; Xin Wang
Journal:  Cell Mol Life Sci       Date:  2013-07-18       Impact factor: 9.261

6.  TDP-43 skeins show properties of amyloid in a subset of ALS cases.

Authors:  John L Robinson; Felix Geser; Anna Stieber; Mfon Umoh; Linda K Kwong; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-11-03       Impact factor: 17.088

7.  TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord.

Authors:  Johannes Brettschneider; Kimihito Arai; Kelly Del Tredici; Jon B Toledo; John L Robinson; Edward B Lee; Satoshi Kuwabara; Kazumoto Shibuya; David J Irwin; Lubin Fang; Vivianna M Van Deerlin; Lauren Elman; Leo McCluskey; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-06-12       Impact factor: 17.088

8.  Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates.

Authors:  Giulia Vinceti; Nicholas Olney; Maria Luisa Mandelli; Salvatore Spina; H Isabel Hubbard; Miguel A Santos-Santos; Christa Watson; Zachary A Miller; Catherine Lomen-Hoerth; Paolo Nichelli; Bruce L Miller; Lea T Grinberg; William W Seeley; Maria Luisa Gorno-Tempini
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-01-22       Impact factor: 4.092

9.  Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.

Authors:  Bilada Bilican; Andrea Serio; Sami J Barmada; Agnes Lumi Nishimura; Gareth J Sullivan; Monica Carrasco; Hemali P Phatnani; Clare A Puddifoot; David Story; Judy Fletcher; In-Hyun Park; Brad A Friedman; George Q Daley; David J A Wyllie; Giles E Hardingham; Ian Wilmut; Steven Finkbeiner; Tom Maniatis; Christopher E Shaw; Siddharthan Chandran
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 10.  Protein aggregation in amyotrophic lateral sclerosis.

Authors:  Anna M Blokhuis; Ewout J N Groen; Max Koppers; Leonard H van den Berg; R Jeroen Pasterkamp
Journal:  Acta Neuropathol       Date:  2013-05-15       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.